[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
Multiple Sclerosis News Today

Fenebrutinib again bests Aubagio in trial at cutting MS relapse rates

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...
Medscape

Trials Offer Mixed Results on BTK Potential for Primary Progressive Multiple Sclerosis

SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...
Pharmabiz

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...